GRIN2A

Overview

GRIN2A (Glutamate Ionotropic Receptor NMDA Type Subunit 2A) encodes a subunit of the NMDA-type glutamate receptor. In cancer genomics, GRIN2A is noted as an infrequently mutated gene in esophagogastric cancer (EGC) and has been observed at lower mutation frequencies in metastatic cohorts compared to primary tumor cohorts, suggesting possible selection against this alteration in the metastatic setting.

Alterations observed in the corpus

  • GRIN2A mutations are less frequently observed in the MSK metastatic esophagogastric cancer (EGC) cohort compared to the TCGA non-MSI-H EGC cohort (q≤0.10), suggesting depletion in the metastatic setting PMID:29122777.

Cancer types (linked)

  • EGC (Esophagogastric Carcinoma): GRIN2A mutations are less frequent in metastatic vs primary EGC (MSK cohort vs TCGA non-MSI-H; q≤0.10) PMID:29122777.

Co-occurrence and mutual exclusivity

Therapeutic relevance

  • No direct therapeutic relevance reported in the corpus.

Open questions

  • Whether the depletion of GRIN2A mutations in metastatic EGC reflects negative selection pressure (tumor-suppressor function in the metastatic setting) or cohort composition differences remains unclear.

Sources

This page was processed by crosslinker on 2026-05-15.